Aug 2026· BMJ Health & Care Informatics· Vol 33, pp. e102045· 0 citations· 28 references
Medicine
TL;DR
Novel artificial intelligence-based clinical decision support (CDS) technology is assessed to develop and validate standard of care (SoC) to streamline the breast MDT meetings in a tertiary cancer centre to deliver a sustainable clinical decision pathway.
Abstract
Abstract Objectives Multidisciplinary team (MDT) meetings are key to delivering cancer care. Increasing caseload and limited resources make them less effective and unsustainable. The aim of this quality improvement project was to assess novel artificial intelligence-based clinical decision support (CDS) technology to develop and validate standard of care (SoC) to streamline the breast MDT meetings in a tertiary cancer centre. Methods A clinical governance group of the MDT approved international guidelines used to develop SoC. Deontics CDS was assessed for its suitability to apply the SoC pathway for benign and malignant breast disease with the exclusion of metastatic and recurrent cancer. Results Patients discussed over the preceding 16 months were added to the platform in cohorts of 50 women: two consisting of 50 women each diagnosed with benign disease (benign A and B: n=100) and three consisting of 50 women each diagnosed with malignant disease (cancer A, B and C: n=150). Concordance between the blinded MDT decision outcomes and SoC recommendations was analysed. This stepwise approach identified knowledge gaps in SoC and refined the CDS. Concordance improved from 82% to 100% in benign and from 94% to 100% in malignant cases. Discussion A sequential process of validating the SoC with data derived from the development of evidence-based SoC protocols based on international guidelines resulted in a final 100% concordance rate between the platform and MDT recommendations for both benign and malignant disease. Conclusions CDS technology could be a milestone in using SoC to deliver a sustainable clinical decision pathway.
Background/Objectives: Breast cancer management relies on multidisciplinary team (MDT) decisions that integrate clinical, radiological, pathological, and patient-related factors. Large language models (LLMs) may support such decisions, but evidence based on real-world cases remains limited. Methods: We evaluated the ag...
G. Dindelegan, Noé Yoshi François Poupel, George Ionuț Golea et al.· Journal of Clinical Medicine· 0 citations
This study demonstrates that deterministic AI can safely automate high-volume clinical pathways with 100% accuracy, providing a “glass-box” alternative to traditional AI models.
IMPORTANCE
Artificial intelligence (AI) is increasingly integrated into clinical decision-making, including applications in pathology, radiomics, and multidisciplinary tumor boards (MDT) for head and neck (ENT) cancer. However, the current scope and performance of AI tools within MDT settings remain unclear.
OBJECTIV...
Karl Bouchard-Locat, Vincent Raby, A. Christopoulos et al.· The Journal of Otolaryngolog...· 0 citations
Current evidence is insufficient to establish improvements in MDT decision quality or patient outcomes, and AI should be regarded as a supervised support tool rather than a replacement for expert multidisciplinary judgment.
A. Nikitaras, S. M. Tsoti, M. Pramateftakis· Frontiers in Oncology· 0 citations
INTRODUCTION
Cancer is a major public health challenge in India, with an estimated 1.4 million new cases each year. Despite this burden, the ratio of oncologists to new cancer patients is critically low, about one specialist per 1600 new diagnoses per year. The AI-driven CDSS could help offset the oncologist shortage i...
M. Shekhawat, A. Nagar, Arpita Gupta et al.· International Journal of Med...· 0 citations
Facilitating shared decision-making (SDM) and incorporating patient decision aids are recommended by the National Institute for Health and Care Excellence (NICE). However, there is a lack of SDM aids for the specific treatment of high-grade glioma patients. The objective of this study was to describe the design a...
J. Hughes, Stephen Price· Neuro-Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.